In vivo and in vitro studies, applying a BRAF-targeted inhibitor (one of MAPK/ERK signaling inhibitors) could increase the expression of tumor antigens and the abundance of tumor-infiltrating immune cells [91]. This evidence concerns the gene BRAF and neoplasm.